PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Biol Blood Marrow Transplant. Author manuscript; available in PMC 2010 November 1.
Published in final edited form as:
PMCID: PMC2782586
NIHMSID: NIHMS154854

Dichotomous Role of Interferon-γ in Allogeneic Bone Marrow Transplant

Abstract

Interferon (IFN)-γ is a pleiotropic cytokine with a central role in innate and adaptive immunity. As a potent pro-inflammatory and anti-tumor cytokine, IFN-γ is conventionally thought to be responsible for driving cellular immune response. On the other hand, accumulating evidence suggests that IFN-γ also has immuno-suppressive activity. An important role for IFN-γ in inhibiting graft-versus-host disease (GVHD) has been demonstrated in murine models, in spite of IFN-γ being one of the key factors amplifying T cell activation during the process of acute GVHD, the major complication and cause of post-transplant mortality in allogeneic bone marrow transplantation (BMT). At the same time, IFN-γ facilitates graft-versus-leukemia (GVL) activity. Dissociation of GVL effects from GVHD has been the ultimate goal of allogeneic BMT in the treatment of hematological malignancies. This paradoxical role of IFN-γ makes modulating its activity a promising strategy to maximize GVL while minimizing GVHD and improve clinical outcomes in BMT. In this review, the effects of IFN-γ on GVHD and GVL are discussed with consideration of the mechanism of IFN-γ action.

Keywords: IFN-γ, Graft-versus-host disease, Graft-versus-leukemia, Allogeneic bone marrow transplant

INTRODUCTION

The interferons were originally discovered as anti-viral agents and were classified into type I and type II according to receptor specificity and sequence homology [1, 2]. IFN-γ is the sole type II IFN and is synthesized by CD4+ Th1 lymphocytes, CD8+ cytotoxic lymphocytes, NK cells, B cells, NKT cells and antigen-presenting cells (APCs) [37]. The regulation of T-cell IFN-γ production includes induction by IL-12 and IL-18 and down-regulation by IL-4, IL-10, transforming growth factor-β and glucocorticoids [813]. Although the immune system appears to develop normally in the absence of pathogen, IFN-γ knock-out mice showed decreased ability in their resistance to bacterial, parasitic and viral infections, suggesting a pivotal role for IFN-γ in the induction of cellular immune response [14]. The current model for the activation of donor T-cells in pathogenesis of graft-versus-host disease (GVHD) implicates IFN-γ as a central regulatory cytokine in the initiation and maintenance of allo-reactivity in allogeneic hematopoietic progenitor cell transplantation (HPCT) [15, 16].

During the development of GVHD, IFN-γ mediates multiple effects including priming of macrophages to produce pro-inflammatory cytokines and nitric oxide (NO) in response to lipopolysaccharide (LPS), up-regulating expression of adhesion molecules, chemokines, major histocompatibility (MHC) II antigen and FAS on APC, resulting in enhanced antigen presentation and recruitment of effector cells [1517]. Increased serum levels of IFN-γ were associated with the severity of acute GVHD in mice and anti-IFN-γ antibodies prevented gastrointestinal GVHD in a CBA→F1 mice model [1821]. While all these data demonstrated that IFN-γ can amplify GVHD, IFN-γ has been shown to also limit GVHD, organ transplantation rejection and autoimmunity [18, 2226]. This paradoxical effects of IFN-γ on GVHD can be partially explained by the observation that IFN-γ can prevent T cell activation directly by inducing T cell growth arrest and apoptosis or indirectly by altering the function of dendritic cells (DC), the most efficient APC population [2730]. The effect of IFN-γ on the immunological microenvironment is also mediated in part by IFN-γ-inducible genes that serve counter-regulatory roles in immune activation, including indoleamine-2, 3-dioxygenase (IDO), inducible nitric oxide synthase (iNOS) and heme oxygenase (HO)-1 that can limit activation of effector T-cells [3032]. This review summarizes current knowledge of the role of IFN-γ on GVHD and GVL based primarily on results from murine model systems, but with attention to potential clinical translation of these findings.

Role of IFN-γ in GVHD and GVL

Effects of exogenous administration of IFN-γ

Based on the immuno-suppressive effects of IFN-γ, investigators have shown that administration of exogenous IFN-γ can prevent GVHD in murine BMT model [24], suggesting the clinical administration of exogenous IFN-γ as a novel strategy to prevent GVHD in allogeneic HPCT [33]. The effect of exogenous IFN-γ administration in murine BMT model systems varies by strain, timing of administration, and intensity of conditioning, which suggest in part the reasons for the conflicting results of the effect of this cytokine on acute GVHD [24, 34]. For example, Brok et al. found that high levels of IFN-γ immediately after BMT is crucial for the prevention of GVHD. Treatment with 50,000 U IFN-γ twice weekly for a period of 5 weeks, starting at the day of BMT, was an optimal treatment protocol to prevent GVHD in a fully H-2-mismatched BMT model. A shorter treatment course(one week with a higher dose of IFN-γ), did not result in significantly improved survival compared to untreated control animals [24]. The timing of IFN-γ administration was a critical factor, since a delay of 3 days from the time of BMT resulted in substantial GVHD-induced mortality [24]. Similarly, as shown by Szebeni et al., administration of IFN-γ from day 2 onwards had no effect on GVHD [35].

Factors that regulate T-cell production of IFN-γ

The central role of donor T-cells in both GVHD and GVL effects has been demonstrated by the markedly reduced frequency and severity of GVHD but increased leukemia relapse in patients given allografts stringently depleted of T-cells [36]. Different methods targeting donor T-cells have been tested in efforts to limit GVHD while preserving GVL [15, 3742]. The administration of IL-12, a potent inducer of IFN-γ production, at the time of allo-BMT had a significant protective effect against GVHD which can be eliminated by anti-IFN-γ antibody or using IFN-γ-deficient T-cells [4345]. Similar results were obtained from administration of IL-18, another potent inducer of IFN-γ production [46, 47].

Of note, growing data has revealed the importance of both host-type and donor-type APCs in regulating T-cell activity in allogeneic BMT model [4851]. Our group initially reported that large numbers of plasmacytoid DC precursors in donor bone marrow are associated with increased relapse after allogeneic BMT [52]. Recently, using an allogeneic murine BMT model (C57BL/6→ B10.BR), the addition of donor IL-12-producing CD11b APC to a graft composed of purified hematopoietic stem cells (HSC) and T-cells was shown to remarkably improve long-term leukemia-free survival without increasing GVHD. Intriguingly, higher number of IFN-γ-producing donor T-cells was seen among recipients of CD11b APC and all of the beneficial effects of donor CD11b APC on post-transplant survival were abrogated when IFN-γ knock-out mice were used as T-cell donors (Table 1) [5355]. These data are consistent with other murine models in which IFN-γ production enhances the GVL activity of donor T-cells while limiting GVHD mortality. In addition, IFN-γ can increase the sensitivity of tumor cells to CTL activity via up-regulation of FAS and MHC expression [22]. More recently, Wang et al. reported that IFN-γ could promote lymphohematopoietic graft-versus-host reactions(LGVHR) and GVL with limited GVHD effects [56].

Table 1
Impact of cotransplant different donor APC subsets with HSC and T cells on Th1/Th2 polarization based on intracellular cytokine staining and serum cytokines in tumor-bearing recipient mice[55].

IFN-γ expression by NK and NKT cells

Natural killer (NK) cells were initially described as radio-resistant host cells that mediated graft rejection in lethally irradiated F1 mice transplanted with parental type T-cell depleted bone marrow [57, 58]. Recent studies have shown that NK cells have dual ability to mediate both bone marrow rejection (host NK cells) and to promote engraftment and GVL activity (donor NK cells). Asai et al. found that mice injected with activated NK cells of donor type survived longer with less GVHD. Furthermore, administration of activated NK cells resulted in significant GVL effects as evidenced by increased survival and fewer lung metastases in mice bearing a colon adenocarcinoma. The GVL effects were associated with high levels of IFN-γ from donor NK and could be partially abrogated by anti-IFN-γ antibody [7]. In addition, activated NK cells are able to prime DC to secrete IL-12 and to induce CD8 T cell memory response through an IFN-γ-dependent pathway [59, 60]. However, other experiments demonstrated that DC activation by NK cells was mediated through direct cell to cell interaction [61]. Thus donor NK cells secreted IFN-γ can augment the anti-tumor activity of the allograft in direct and indirect mechanisms.

NKT cells have been demonstrated to regulate suppressive responses through local IFN-γ production in transplantation rejection, autoimmune diseases and GVHD [62]. In vitro expansion and transplantation of cytolytic CD8+ NKT cells reduced GVHD as compared to unfractionated donor splenocytes [6]. Type II NKT cells that lack Vα14Jα18 expression and are CD1d-restricted, protect against GVHD in an IFN-γ-dependent way compared to type I Vα14Jα18 TCR+ NKT cells [63, 64].

IFN-γ expression by CD25+CD4+ regulatory T cells

IFN-γ is one of the major mediators of the immunosuppressive role of CD25+CD4+ regulatory T (T reg) cells [65, 66]. Stimulation of ex vivo expanded T reg cells with alloantigen can induce rapid and transient IFN-γ production which causes immune suppression by multiple mechanisms. IFN-γ can directly inhibit T cell activation by inducing apoptosis or retarding T-cell proliferation. IFN-γ also acts on APC in close proximity to T reg limiting their ability to activate T-cells. IFN-γ enhances expression of iNOS and IDO, the release of which will subsequently prevent T cell proliferation and activation [31]. Several reports have shown that depletion of T reg cells accelerates GVHD, and addition of T reg cells reduces GVHD. In a murine BMT model, Negrin et al. showed that inoculation of donor T reg into tumor-bearing recipients inhibited expansion of alloreactive T-cells and GVHD. However, the percentage of IFN-γ-producing conventional T-cells and serum IFN-γ in mice that received grafts containing T reg cells were also decreased [67]. The differential effect of IFN-γ secreted by T reg in these models can be explained by the various roles of IFN-γ in different stages of GVHD. Very early expression of IFN-γ by T reg during the phase of T cell activation could lead to the initiation of counter-regulatory effects that limit the extent of T-cell alloactivity.

IFN-γ expression by mesenchymal stem cells (MSCs)

Accumulating data have showed that CD34 fibroblast-like MSCs can be potently immunosuppressive and inhibit GVHD in murine BMT models. More intriguingly, MSCs expanded ex vivo have been used to successfully treat ongoing, acute and steroid-refractory GVHD in clinical trials [68, 69]. Mechanisms of suppression of GVHD by MSCs involve their effects on other immune cells including T-cells, APCs, NK cells, and B cells [70, 71]. A recent study from Zhang et al. showed that MSCs could not only drive immature DC or mature DC to escape from apoptosis, but also induce mature DC into a distinct regulatory DC population capable of inhibiting T-cell proliferation, activity and IFN-γ production through a Jagged-2-dependent mechanism [72]. Blockade of IFN-γ pathway, using IFN-γ knock out T cells or IFN-γ receptor deficient MSCs abolished the immunosuppressive effect of MSCs[71, 73]. IFN-γ can also stimulate the production of IDO by MSCs, which in turn inhibited the proliferation of activated T or NK cells[74]. However, Shi et al. reported that IFN-γ is necessary but not sufficient for the immunosuppressive function of MSCs. IFN-γ must be present along with any one of three other proinflammatory cytokines, TNF-α, IL-1α, or IL-1β to induce immunosuppression by MSCs [73]. More recently, Polchert et al. found that MSCs, pre-treated with IFN-γ, were activated and could suppress GVHD more efficiently than MSCs that were not activated. The MSC activation was dependent on the magnitude of IFN-γ exposure, with increased IFN-γ exposure leading to increased MSC suppression of GVHD. These IFN-γ “activated MSC” present a new strategy for preventing GVHD using fewer MSC. Taken together, local production of IFN-γ by T reg, NK cells or activated conventional T-cells may induce host-type MSC to become activated and more immunosuppressive, thereby limiting GVHD [75]. The possibility that MSC may also limit GVL activity of donor T-cells is of some concern, a recent clinical trail of the pre-captive administration of MSC was characterized by an excess of early leukemia relapse [76] (Figure 1).

Figure 1
IFN-γ-producing cells show different effects on GVHD and GVL

Molecular and cellular effects of IFN-γ

IFN-γ limits expansion of allo-reactive T-cells

IFN-γ can suppress GVHD by inhibiting activation and expansion of both donor CD4+ and CD8+ T-cells by inducing apoptosis and cell cycle arrest [22, 77]. The mechanism of alloreactive T cell apoptosis induced by IFN-γ in transplant model is not completely clear. In vitro studies have indicated that upon IFN-γ treatment, FAS is upregulated and activated to induce apoptosis in a series of cell lines [78, 79]. In vivo studies have consistently shown that IFN-γ regulates expression of both FAS/FASL on alloreactive donor T-cells. In addition, many other IFN-γ-regulated genes, including IDO on APC were also found to be involved in IFN-γ-induced apoptosis and will be discussed below.

Global gene expression profiles of livers after experimental allogeneic and syngeneic BMT using oligonucleotide microarray showed up-regulation of IFN-γ–inducible genes, including MHC class II molecules, and genes related to leukocyte trafficking at day 7 prior to the development of GVHD. At day 35 after allogeneic BMT, when hepatic GVHD was histologically evident, genes related to cellular effectors and acute-phase proteins were up-regulated, whereas genes largely related to metabolism and endocrine function were down-regulated[80]. These data suggested that the temporal sequence of increased expression of genes associated with the attraction and activation of donor T-cells induced by IFN-γ early after BMT is important in the initiation of GVHD.

IFN-γ induces IDO expression in APC and host epithelial cells

IDO is an intracellular heme-containing enzyme that catalyzes the essential amino acid tryptophan. IDO gene can be prominently up-regulated by IFN-γ in a promoter-dependent way through STAT1 and IRF-1 binding sites (GAS and ISRE) or by activation of PI3K, JNK or NF-κB [31, 81]. Broad evidence supports IDO as an important mediator of peripheral tolerance induced by IFN-γ. IDO-mediated immunosuppression includes depletion of tryptophan in the microenvironment and local secretion of the products of tryptophan metabolism that have direct immuno-suppressive effect. For instance, kynurenine and 3-hydroxykynurenine are cytotoxic to human T-cells, B and NK cells. Other metabolic products 3-hydroxyanthranilic acid and quinolinic acid are able to induce Th1 cell apoptosis [31, 82]. In addition, IDO can also help maintaining T regs in their normal suppressive phenotype [83] (Figure 2). Interestingly, a recent study showed that transgenic expression of IDO resulted in increased tubular epithelial cell apoptosis in a FAS/FASL-dependent, caspase-8-mediated mechanism, suggesting that integration of a network of IFN-γ-regulated pathways can result in counter-regulatory effects including cell death [84]. Based on these interesting findings, use of a small molecule inhibitor of IDO D1-MT to reverse the immuno-suppression, has entered a phase I clinical trial.

Figure 2
Role of IFN-γ during the development of GVHD and GVL

By using IDO knock-out mice as recipients, Jasperson and colleagues demonstrated that without host IDO expression, mice experienced markedly higher GVHD morbidity, suggesting that IDO can act at sites of GVHD to decrease T-cell proliferation. Thus modulation of IDO synthesis in GVHD target organs may represent an interesting strategy for limiting gut GVHD [85]. Intriguingly, a recent clinical study showed that DCs and monocytes from HPCT patients developing acute GVHD were less able to up-regulate IDO on exposure to IFN-γ than healthy volunteers or those with milder GVHD [86]. However, the mechanism of IDO expression in DC on the regulation of T-cell alloactivity during GVHD is not completely understood. Recently, using a murine transplant model, we found that donor T cell-derived IFN-γ causes up-regulation of IDO in DCs, suggesting that time and tissue-dependent IFN-γ synthesis by donor T-cells may initiate counter-regulatory immune mechanisms that limit overall GVHD activity while permitting selective GVL effects (Figure 2,,33).

Figure 3
IFN-γ-induced IDO expression on host epithelial cells inhibits GVHD

CONCLUSION

The dual effects of IFN-γ on GVHD and GVL make understanding the role of local production of IFN-γ during the initial interaction of donor T-cells and NK cells with host- and donor-type APC critical to achieve the goal of separating GVL from GVHD. The effects of IFN-γ are dependent upon local concentrations in the lymph node or epithelial microenvironments, the timing of synthesis or exogenous administration, and the stage of the development of the allo-immune response in transplant. However, much remains unknown about the precise pathways of IFN-γ action and the reciprocal actions of IFN-γ derived from different cell subsets. Another challenge is to understand the mechanisms by which IFN-γ signaling and cellular effects integrate with other cytokines, since cells in vivo are not exposed to a single stimulus in isolation. Better murine models and analysis of local effects of the cytokine mileau on T-cells at multiple time points and tissue sites in the first few hours and days after clinical allogeneic HPCT will help elucidate the role of IFN-γ in inducing GVL activities while limiting GVHD. Understanding of these questions should lead to the development of novel strategies for patients undergoing BMT to maximize GVL with limited GVHD.

Acknowledgments

The authors thank Regina M. Daniel for preparing the final manuscript.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

1. Farrar MA, Schreiber RD. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol. 1993;11:571–611. [PubMed]
2. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75:163–189. [PubMed]
3. Frucht DM, Fukao T, Bogdan C, Schindler H, O’Shea JJ, Koyasu S. IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol. 2001;22:556–560. [PubMed]
4. Flaishon L, Hershkoviz R, Lantner F, et al. Autocrine secretion of interferon gamma negatively regulates homing of immature B cells. J Exp Med. 2000;192:1381–1388. [PMC free article] [PubMed]
5. Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol. 2000;1:475–482. [PubMed]
6. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 2001;97:2923–2931. [PubMed]
7. Asai O, Longo DL, Tian ZG, et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest. 1998;101:1835–1842. [PMC free article] [PubMed]
8. Trotta R, Col JD, Yu J, et al. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol. 2008;181:3784–3792. [PMC free article] [PubMed]
9. Munder M, Mallo M, Eichmann K, Modolell M. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation. J Exp Med. 1998;187:2103–2108. [PMC free article] [PubMed]
10. Fukao T, Matsuda S, Koyasu S. Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN-gamma production by dendritic cells. J Immunol. 2000;164:64–71. [PubMed]
11. Elenkov IJ. Glucocorticoids and the Th1/Th2 balance. Ann N Y Acad Sci. 2004;1024:138–146. [PubMed]
12. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006;24:99–146. [PubMed]
13. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol. 2004;22:929–979. [PubMed]
14. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science. 1993;259:1739–1742. [PubMed]
15. Sun Y, Tawara I, Toubai T, Reddy P. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res. 2007;150:197–214. [PMC free article] [PubMed]
16. Ferrara JL, Cooke KR, Teshima T. The pathophysiology of acute graft-versus-host disease. Int J Hematol. 2003;78:181–187. [PubMed]
17. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373:1550–1561. [PMC free article] [PubMed]
18. Yang YG, Wang H, Asavaroengchai W, Dey BR. Role of Interferon-gamma in GVHD and GVL. Cell Mol Immunol. 2005;2:323–329. [PubMed]
19. Dickinson AM, Sviland L, Hamilton PJ, et al. Cytokine involvement in predicting clinical graft-versus-host disease in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 1994;13:65–70. [PubMed]
20. Takatsuka H, Yamada S, Okamoto T, et al. Predicting the severity of intestinal graft-versus-host disease from leukotriene B4 levels after bone marrow transplantation. Bone Marrow Transplant. 2000;26:1313–1316. [PubMed]
21. Mowat AM. Antibodies to IFN-gamma prevent immunologically mediated intestinal damage in murine graft-versus-host reaction. Immunology. 1989;68:18–23. [PubMed]
22. Yang YG, Qi J, Wang MG, Sykes M. Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells. Blood. 2002;99:4207–4215. [PubMed]
23. Tarrant TK, Silver PB, Wahlsten JL, et al. Interleukin 12 protects from a T helper type 1-mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon gamma, nitric oxide, and apoptosis. J Exp Med. 1999;189:219–230. [PMC free article] [PubMed]
24. Brok HP, Vossen JM, Heidt PJ. IFN-gamma-mediated prevention of graft-versus-host disease: pharmacodynamic studies and influence on proliferative capacity of chimeric spleen cells. Bone Marrow Transplant. 1998;22:1005–1010. [PubMed]
25. Brok HP, Heidt PJ, van der Meide PH, Zurcher C, Vossen JM. Interferon-gamma prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Immunol. 1993;151:6451–6459. [PubMed]
26. Hidalgo LG, Halloran PF. Role of IFN-gamma in allograft rejection. Crit Rev Immunol. 2002;22:317–349. [PubMed]
27. Asavaroengchai W, Wang H, Wang S, et al. An essential role for IFN-gamma in regulation of alloreactive CD8 T cells following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2007;13:46–55. [PMC free article] [PubMed]
28. Liu Y, Janeway CA., Jr Interferon gamma plays a critical role in induced cell death of effector T cell: a possible third mechanism of self-tolerance. J Exp Med. 1990;172:1735–1739. [PMC free article] [PubMed]
29. Frasca L, Nasso M, Spensieri F, et al. IFN-gamma arms human dendritic cells to perform multiple effector functions. J Immunol. 2008;180:1471–1481. [PubMed]
30. Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 2002;297:1867–1870. [PubMed]
31. King NJ, Thomas SR. Molecules in focus: indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol. 2007;39:2167–2172. [PubMed]
32. Wood KJ, Sawitzki B. Interferon gamma: a crucial role in the function of induced regulatory T cells in vivo. Trends Immunol. 2006;27:183–187. [PubMed]
33. Wall DA, Hamberg SD, Reynolds DS, Burakoff SJ, Abbas AK, Ferrara JL. Immunodeficiency in graft-versus-host disease. I. Mechanism of immune suppression. J Immunol. 1988;140:2970–2976. [PubMed]
34. Brok HP, Vossen JM, Heidt PJ. Interferon-gamma-mediated prevention of graft-versus-host disease: development of immune competent and allo-tolerant T cells in chimeric mice. Bone Marrow Transplant. 1997;19:601–606. [PubMed]
35. Szebeni J, Wang MG, Pearson DA, Szot GL, Sykes M. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease. Transplantation. 1994;58:1385–1393. [PubMed]
36. Butturini A, Gale RP. T cell depletion in bone marrow transplantation for leukemia: current results and future directions. Bone Marrow Transplant. 1988;3:185–192. [PubMed]
37. Li JM, Giver CR, Waller EK. Graft engineering using ex vivo methods to limit GVHD: fludarabine treatment generates superior GVL effects in allogeneic BMT. Exp Hematol. 2006;34:895–904. [PubMed]
38. Li JM, Gorechlad J, Larsen CP, Waller EK. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40–CD154 blockade in allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2006;12:1239–1249. [PubMed]
39. Waller EK, Giver CR, Rosenthal H, et al. Facilitating T-cell immune reconstitution after haploidentical transplantation in adults. Blood Cells Mol Dis. 2004;33:233–237. [PubMed]
40. Hossain MS, Roback JD, Pollack BP, Jaye DL, Langston A, Waller EK. Chronic GvHD decreases antiviral immune responses in allogeneic BMT. Blood. 2007;109:4548–4556. [PubMed]
41. Hossain MS, Roback JD, Wang F, Waller EK. Host and donor immune responses contribute to antiviral effects of amotosalen-treated donor lymphocytes following early posttransplant cytomegalovirus infection. J Immunol. 2008;180:6892–6902. [PubMed]
42. Giver CR, Montes RO, Mittelstaedt S, et al. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects. Biol Blood Marrow Transplant. 2003;9:616–632. [PubMed]
43. Sykes M, Szot GL, Nguyen PL, Pearson DA. Interleukin-12 inhibits murine graft-versus-host disease. Blood. 1995;86:2429–2438. [PubMed]
44. Yang YG, Sergio JJ, Pearson DA, Szot GL, Shimizu A, Sykes M. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice. Blood. 1997;90:4651–4660. [PubMed]
45. Yang YG, Sykes M. The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD. Leuk Lymphoma. 1999;33:409–420. [PubMed]
46. Reddy P, Teshima T, Kukuruga M, et al. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med. 2001;194:1433–1440. [PMC free article] [PubMed]
47. Reddy P, Ferrara JL. Role of interleukin-18 in acute graft-vs-host disease. J Lab Clin Med. 2003;141:365–371. [PubMed]
48. Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG. Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat Med. 2005;11:1299–1305. [PubMed]
49. Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med. 2005;11:1244–1249. [PubMed]
50. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412–415. [PubMed]
51. Lonial S, Torre C, David E, Harris W, Arellano M, Waller EK. Regulation of alloimmune responses by dendritic cell subsets. Exp Hematol. 2008;36:1309–1317. [PubMed]
52. Waller EK, Rosenthal H, Jones TW, et al. Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood. 2001;97:2948–2956. [PubMed]
53. Li JM, Waller EK. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2004;10:540–551. [PubMed]
54. Li JM, Waller EK. The yin and yang of adaptive immunity in allogeneic hematopoietic cell transplantation: donor antigen-presenting cells can either augment or inhibit donor T cell alloreactivity. Adv Exp Med Biol. 2007;590:69–87. [PubMed]
55. Li JM, Southerland L, Lu Y, et al. Activation, immune polarization, and graft-versus-leukemia activity of donor T-cells are regulated by specific subsets of donor bone marrow antigen-presenting cells in allogeneic hematopoietic stem cell transplantation. J Immunol. In revision. [PMC free article] [PubMed]
56. Wang H, Asavaroengchai W, Yeap BY, et al. Paradoxical effects of IFN-gamma in graft-versus-host disease reflect promotion of lymphohematopoietic graft-versus-host reactions and inhibition of epithelial tissue injury. Blood. 2009;113:3612–3619. [PubMed]
57. Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer. 1975;16:230–239. [PubMed]
58. Kiessling R, Petranyi G, Klein G, Wigzel H. Genetic variation of in vitro cytolytic activity and in vivo rejection potential of non-immunized semi-syngeneic mice against a mouse lymphoma line. Int J Cancer. 1975;15:933–940. [PubMed]
59. Mocikat R, Braumuller H, Gumy A, et al. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity. 2003;19:561–569. [PubMed]
60. Adam C, King S, Allgeier T, et al. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood. 2005;106:338–344. [PubMed]
61. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med. 2002;195:327–333. [PMC free article] [PubMed]
62. Fujii S. Application of natural killer T-cells to posttransplantation immunotherapy. Int J Hematol. 2005;81:1–5. [PubMed]
63. Ellison CA, Taniguchi M, Fischer JM, Hayglass KT, Gartner JG. Graft-versus-host disease in recipients of grafts from natural killer T cell-deficient (Jalpha281(−/−)) donors. Immunology. 2006;119:338–347. [PubMed]
64. Kim JH, Choi EY, Chung DH. Donor bone marrow type II (non-Valpha14Jalpha18 CD1d-restricted) NKT cells suppress graft-versus-host disease by producing IFN-gamma and IL-4. J Immunol. 2007;179:6579–6587. [PubMed]
65. Sawitzki B, Kingsley CI, Oliveira V, Karim M, Herber M, Wood KJ. IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J Exp Med. 2005;201:1925–1935. [PMC free article] [PubMed]
66. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345–352. [PubMed]
67. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9:1144–1150. [PubMed]
68. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579–1586. [PubMed]
69. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439–1441. [PubMed]
70. Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol. 2006;36:2566–2573. [PubMed]
71. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105:1815–1822. [PubMed]
72. Zhang B, Liu R, Shi D, et al. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood. 2009;113:46–57. [PubMed]
73. Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008;2:141–150. [PubMed]
74. Krampera M, Cosmi L, Angeli R, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24:386–398. [PubMed]
75. Polchert D, Sobinsky J, Douglas G, et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008;38:1745–1755. [PMC free article] [PubMed]
76. Ning H, Yang F, Jiang M, et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia. 2008;22:593–599. [PubMed]
77. Berner V, Liu H, Zhou Q, et al. IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med. 2007;13:354–360. [PubMed]
78. Fluhr H, Krenzer S, Stein GM, et al. Interferon-gamma and tumor necrosis factor-alpha sensitize primarily resistant human endometrial stromal cells to Fas-mediated apoptosis. J Cell Sci. 2007;120:4126–4133. [PubMed]
79. Shin EC, Ahn JM, Kim CH, et al. IFN-gamma induces cell death in human hepatoma cells through a TRAIL/death receptor-mediated apoptotic pathway. Int J Cancer. 2001;93:262–268. [PubMed]
80. Ichiba T, Teshima T, Kuick R, et al. Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays. Blood. 2003;102:763–771. [PubMed]
81. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol. 2007;7:817–823. [PubMed]
82. Terness P, Bauer TM, Rose L, et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med. 2002;196:447–457. [PMC free article] [PubMed]
83. Sharma MD, Hou DY, Liu Y, et al. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood. 2009;113:6102–6111. [PubMed]
84. Mohib K, Guan Q, Diao H, Du C, Jevnikar AM. Proapoptotic activity of indoleamine 2,3-dioxygenase expressed in renal tubular epithelial cells. Am J Physiol Renal Physiol. 2007;293:F801–812. [PubMed]
85. Jasperson LK, Bucher C, Panoskaltsis-Mortari A, et al. Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood. 2008;111:3257–3265. [PubMed]
86. Steckel NK, Kuhn U, Beelen DW, Elmaagacli AH. Indoleamine 2,3-dioxygenase expression in patients with acute graft-versus-host disease after allogeneic stem cell transplantation and in pregnant women: association with the induction of allogeneic immune tolerance? Scand J Immunol. 2003;57:185–191. [PubMed]